Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.2K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.2K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

891
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
891
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

538
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
538
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

643
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
643
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.3K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.3K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.3K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Traumatic high flow priapism in a child - the role of Colour Doppler Ultrasound and gelfoam embolotherapy for effective management.

CVIR endovascular·2026
Same author

Feasibility pilot study of the use of ultra-low dose iodinated contrast agent for endovascular procedures in patients with chronic limb-threatening ischemia and renal impairment: the ULTRA-LOW study.

CVIR endovascular·2026
Same author

Paclitaxel-Coated Balloon Therapy for Refractory Ureteral Stenosis in a Kidney Transplant Recipient.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Assessing the MYNX CONTROL arterial vascular closure device after catheterization procedures that enter the body through the femoral arteries.

Expert review of medical devices·2026
Same author

Correction: Schubert et al. Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery. <i>Life</i> 2026, <i>16</i>, 73.

Life (Basel, Switzerland)·2026
Same author

Acute intraprocedural cardiac tamponade during microwave ablation of hepatocellular carcinoma in segment 2: A case report of emergency percutaneous salvage.

Radiology case reports·2026

Related Experiment Video

Updated: Feb 11, 2026

Induction of Cerebral Arterial Gas Embolism in Rat
06:26

Induction of Cerebral Arterial Gas Embolism in Rat

Published on: October 18, 2024

899

Transcatheter Arterial Embolization for Bleeding Peptic Ulcers: A Multicenter Study.

Stavros Spiliopoulos1, Riccardo Inchingolo2,3, Pierleone Lucatelli4

  • 12nd Department of Radiology, Interventional Radiology Unit, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. stavspiliop@med.uoa.gr.

Cardiovascular and Interventional Radiology
|April 20, 2018
PubMed
Summary

Transcatheter arterial embolization (TAE) is a highly effective second-line treatment for severe peptic ulcer bleeding (PUB) after failed endoscopy. This study shows 100% technical success and a high survival rate, with minimal re-bleeding.

Keywords:
Peptic ulcerTranscatheter arterial embolizationUpper gastrointestinal bleeding

More Related Videos

Embolic Middle Cerebral Artery Occlusion MCAO for Ischemic Stroke with Homologous Blood Clots in Rats
09:11

Embolic Middle Cerebral Artery Occlusion MCAO for Ischemic Stroke with Homologous Blood Clots in Rats

Published on: September 17, 2014

27.9K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.4K

Related Experiment Videos

Last Updated: Feb 11, 2026

Induction of Cerebral Arterial Gas Embolism in Rat
06:26

Induction of Cerebral Arterial Gas Embolism in Rat

Published on: October 18, 2024

899
Embolic Middle Cerebral Artery Occlusion MCAO for Ischemic Stroke with Homologous Blood Clots in Rats
09:11

Embolic Middle Cerebral Artery Occlusion MCAO for Ischemic Stroke with Homologous Blood Clots in Rats

Published on: September 17, 2014

27.9K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.4K

Area of Science:

  • Interventional Radiology
  • Gastroenterology
  • Vascular Surgery

Background:

  • Peptic ulcer bleeding (PUB) is a significant cause of upper gastrointestinal hemorrhage.
  • Endoscopic hemostasis is the first-line treatment but often fails in severe cases.
  • Transcatheter arterial embolization (TAE) offers an alternative therapeutic option.

Purpose of the Study:

  • To evaluate the efficacy and safety of TAE in patients with severe PUB who failed endoscopic hemostasis.
  • To assess technical success, survival rates, re-bleeding, and complication rates associated with TAE.

Main Methods:

  • Retrospective, multicenter study of 44 patients with severe PUB from peptic ulcers.
  • Patients underwent TAE after failed endoscopic hemostasis between 2012 and 2017.
  • Outcomes included technical success, 30-day and overall survival, re-bleeding, and complications.

Main Results:

  • 100% technical success rate for TAE in achieving vessel occlusion.
  • 30-day survival rate was 79.5%, with no deaths from hemorrhage.
  • Re-bleeding occurred in 4.5% of cases and was successfully managed; major complications were also 4.5%.

Conclusions:

  • TAE is a technically successful and clinically effective second-line treatment for peptic ulcer bleeding.
  • The low rates of re-bleeding and manageable complications underscore TAE's utility.
  • TAE should be considered a valuable option following endoscopic treatment failure for PUB.